Refractory Diffuse Large B-cell Lymphoma

Refractory Diffuse Large B-cell Lymphoma After First-line Immuno-CT: Treatment Options and Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03664336

Enrollment

104

Registered

2018-09-10

Start date

2016-11-30

Completion date

2018-01-31

Last updated

2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-cell Lymphoma

Keywords

diffuse large B-cell lymphoma, refractory, rituximab

Brief summary

In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

-≥18 years of age * diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017 * presented with refractory disease in response to front-line therapies * including anthracycline-based chemo and a monoclonal anti-CD20 antibody

Exclusion criteria

* Patients with a history of indolent lymphoma, * Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma

Design outcomes

Primary

Measure	Time frame	Description
Outcome according to pattern of refractoriness	Up to 4 years	OS was defined as the time from first relapse, or progression, to death from any cause.

Secondary

Measure	Time frame	Description
Outcome according to pattern of refractoriness	Up tp 24 months	EFS was defined as the time from first relapse, or progression, to the next event (defined as either second relapse/progression, change of therapy, or death from any cause). Patients who did not experience an event were censored at the last follow-up.

Countries

France

Outcome results